Halsa Pharmaceuticals Announces Promising Results from Preclinical Studies on Recombinant Human Zinc-a2-glycoprotein (ZAG)
Preclinical studies conducted by Halsa Pharmaceuticals, Inc. have demonstrated the potential therapeutic benefits of recombinant human Zinc-a2-glycoprotein (ZAG) in treating obesity and Type 2 diabetes. The studies showed that ZAG induced a significant loss of body weight in mice, normalized diabetic glucose tolerance curves, and exhibited low acute toxicity. These findings suggest that ZAG may have a potential therapeutic application in the treatment of obesity and Type 2 diabetes.
Key Takeaways:
- Recombinant human Zinc-a2-glycoprotein (ZAG) induced a significant loss of body weight in mice, with a weight loss of 3.5g in five days.
- ZAG produced a normalization of the diabetic glucose tolerance curve after three days of treatment, suggesting a potential therapeutic application in the treatment of obesity and Type 2 diabetes.
- The studies demonstrated low acute toxicity of ZAG, with a medium prevalence in the human body.
- Professor Michael J. Tisdale, Aston University, Birmingham, U.K., inventor of ZAG as a therapeutic, stated that ZAG regulates the metabolic hallmarks of Type 2 diabetes as well as obesity.
- Halsa Pharmaceuticals, Inc. announced the results at the Obesity 2009 conference, one of the largest scientific conferences in the field of obesity.
Statistics:
- Weight loss in mice: 3.5g in five days
- Rise in temperature: 0.4[degrees]C, suggesting an increase in energy expenditure
- Time to normalize diabetic glucose tolerance curve: three days
- Prevalence of ZAG in the human body: medium
- Number of mice studied: unknown (not specified in the text)
Sources:
- Halsa Pharmaceuticals, Inc.
- Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society. October 24-28.
- Professor Michael J. Tisdale, Aston University, Birmingham, U.K.
- Obesity & Diabetes Week via NewsRx.com. Copyright 2009.